|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0000 - 0.0000|
|52 Week Range|
|PE Ratio (TTM)||21.58|
|Dividend & Yield||1.03 (3.24%)|
|1y Target Est||N/A|
Roche Holdings AG (RHHBY) announced that the FDA has put a partial clinical hold on a phase Ib and phase I/II b trials evaluating immunotherapy drug Tecentriq.
In 2016, Roche Holding AG sold $3 billion worth of its blockbuster biotechnology drug Avastin. Last week, the U.S. Food and Drug Administration approved what’s expected to be a less-expensive version.
Amgen sets to offer a competitor to Roche's Avastin.